Fenway Health is proud to share that the FDA has just approved YEZTUGO, the first long-acting injectable PrEP medication administered just twice a year. This is a major milestone in the effort to expand access, choice, and convenience for people seeking HIV prevention options.
Fenway played a key role in this breakthrough as the only clinical trial site in New England to enroll participants in PURPOSE-2, one of the two pivotal studies that led to this approval.
We know many of our patients are excited about this new, long-acting option. Here’s what you need to know right now:
- While YEZTUGO is FDA-approved, insurance coverage is still being finalized. That means we don’t yet know the out-of-pocket costs or how coverage will vary by plan. These details will likely become clearer in the coming months.
- We’re aiming to offer YEZTUGO at Fenway starting in early August 2025. Between now and then, we are preparing our systems, training staff, and finalizing protocols to ensure the medication can be offered safely, efficiently, and equitably.
We are committed to providing you with timely updates as more information becomes available. Our goal is to ensure that every patient who wants this option has a clear and affordable pathway to access it.
Thank you for continuing to trust Fenway with your care. We’re excited to offer this new tool in HIV prevention and will be with you every step of the way.